<?xml version="1.0" ?>
<document id="697b9d764f13648fa38faa8d93fefde6049d6517">
  <chunk id="697b9d764f13648fa38faa8d93fefde6049d6517.c0" text="Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing"/>
  <chunk id="697b9d764f13648fa38faa8d93fefde6049d6517.c1" text="Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (Amgen British Columbia Inc), we produced a panel of neutralizing Human monoclonal antibodies (HmAbs) that could specifically bind to the ectodomain of the SARS-CoV spike (S) glycoprotein. Some of the HmAbs were S1 domain specific, while some were not. In this study, we describe non-S1 binding neutralizing HmAbs that can specifically bind to the conserved S2 domain of the S protein. However, unlike the S1 specific HmAbs, the S2 specific HmAbs can neutralize pseudotyped viruses expressing different S proteins containing receptor binding domain sequences of various clinical isolates. These data indicate that HmAbs which bind to conserved regions of the S protein are more suitable for conferring protection against a wide range of SARS-CoV variants and have implications for generating therapeutic antibodies or subunit vaccines against other enveloped viruses. Citation: Elshabrawy HA, Coughlin MM, Baker SC, Prabhakar BS (2012) Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing. PLoS ONE 7(11): e50366.">
    <entity charOffset="7-11" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e0" ontology_id="GO_0004617" text="sera" type="gene_function"/>
    <entity charOffset="114-120" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e1" ontology_id="HP_0012828" text="Severe" type="phenotype"/>
    <entity charOffset="121-126" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e2" ontology_id="HP_0011009" text="Acute" type="phenotype"/>
    <entity charOffset="586-593" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e3" ontology_id="GO_0005488" text="binding" type="gene_function"/>
    <entity charOffset="833-840" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e4" ontology_id="GO_0005488" text="binding" type="gene_function"/>
    <pair e1="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e0" e2="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e1" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.p0" relation="true"/>
    <pair e1="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e0" e2="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e2" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.p1" relation="true"/>
    <pair e1="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e1" e2="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e3" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.p2" relation="true"/>
    <pair e1="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e1" e2="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e4" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.p3" relation="true"/>
    <pair e1="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e2" e2="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e3" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.p4" relation="true"/>
    <pair e1="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e2" e2="697b9d764f13648fa38faa8d93fefde6049d6517.c1.e4" id="697b9d764f13648fa38faa8d93fefde6049d6517.c1.p5" relation="true"/>
  </chunk>
</document>
